|

Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer

RECRUITINGSponsored by National Taiwan University Hospital
Actively Recruiting
SponsorNational Taiwan University Hospital
Started2025-02-06
Est. completion2027-02-28
Eligibility
Age20 Years – 85 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06984250

Summary

Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy

Eligibility

Age: 20 Years – 85 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS).
* Patients undergoing breast-conserving surgery
* Age ≥ 20 years
* Karnofsky Performance Status (KPS) ≥70%
* Life expectancy ≥ 5 years
* Adequate renal and hepatic function

Exclusion Criteria:

* Pregnant patients
* Patients requiring re-irradiation of the thoracic region

Conditions4

Breast CancerCancerDuctal Breast Carcinoma in SituEarly Breast Cancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.